Table 3.

Study 3201 Change from Baseline for Serum Urate by SLC2A9 Variant rs7442295 Genotype Subgroups (μmol/L).

Visit	Genotype	Iloperidone LS Mean Change (SE), n	Placebo LS Mean Change (SE), n	LS Mean Difference (95% CI)	p-value
Day 28	AA	25.74 (6.53), 73	−6.17 (6.47), 74	31.91 (14.82, 49)	0.0003
Day 28	AG	24.62 (7.61), 51	9.78 (6.67), 68	14.84 (−4.18, 33.86)	0.1256
Day 28	GG	40.09 (12.36), 18	−16.86 (15.37), 12	56.95 (18.91, 94.99)	0.0035

Results of ANCOVA model of change from Baseline to either Day 28 or EOS evaluations for serum urate in Study 3201. LS mean change from Baseline to Day 28 shown for each genotype, with standard error (SE) and n for observed cases. LS means difference shown with 95% CI.

ANCOVA analysis of covariance, CI confidence interval, LS least squares.

Baseline is defined as the latest non-missing observation across all the visits in the Screening Phase before the first dose of study medication. LS means, CIs, and p-values are based on ANCOVA model with main effects of treatment group, pooled site, genetic group and baseline, interaction effects of treatment group and genetic group as a covariate. P-value represents the difference between iloperidone and placebo groups.